Dukaro (amlodipine/fimasartan/rosuvastatin) / Boryung Group - LARVOL DELTA

FIRST: Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia (clinicaltrials.gov) - P3; N=138; Completed; Sponsor: Boryung Pharmaceutical Co., Ltd; Recruiting ➔ Completed; Trial completion date: May 2019 ➔ Dec 2018; Trial primary completion date: Aug 2018 ➔ Dec 2018

Clinical • Monotherapy • Trial completion • Trial completion date • Trial primary completion date